Wall Street equity research analysts tracking LENZ Therapeutics maintain a consensus "Moderate Buy" rating on the stock, supported by average 12-month price targets ranging significantly higher than its current trading valuation. While individual forecasts span from conservative institutional estimates near $7.00 up to aggressive bull-case targets reaching $50.00, the consensus average price target hovers near $28.80 per share, reflecting strong projected upside tied to the commercial adoption of its FDA-approved ophthalmic treatments.